GALCHIMIA SA

Their core work

Galchimia is a Spanish chemistry SME that provides contract research and process development services, specializing in the design and scale-up of chemical and biotechnological manufacturing processes. In their H2020 work, they contributed to building sustainable, scalable production platforms — first for clinically relevant compounds requiring GMP-compatible manufacturing, then for bio-based natural products using engineered microbial cell factories. Their core applied skill is translating laboratory chemistry into reproducible, medium-to-large-scale manufacturing workflows. They sit at the boundary between organic/medicinal chemistry and emerging synthetic biology, making them a practical execution partner for projects that need to move compounds from bench to process scale.

What they specialise in

How they've shifted over time

In their first H2020 project (NANOFACTURING, 2015–2019), Galchimia worked on conventional chemical manufacturing process scale-up, specifically for clinically relevant compounds — work rooted in traditional process chemistry and pharmaceutical manufacturing. Their second project (SHIKIFACTORY100, 2019–2023) marks a clear shift toward synthetic biology: microbial chassis, metabolic engineering, and cell factory design, with a focus on bio-based natural products. This transition suggests the company has been building competence in biotechnology-enabled chemistry, moving from classical scale-up work toward living-cell production systems as a complementary or replacement manufacturing route.

Galchimia is moving from traditional process chemistry toward bio-based manufacturing — making them a relevant partner for projects where fermentation or engineered microbes are replacing conventional chemical synthesis routes.

How they like to work

Galchimia has participated exclusively as a consortium partner across both projects, never leading as coordinator — a consistent specialist contributor pattern. With 20 unique partners across 10 countries from just two projects, they engage in sizeable international consortia rather than tight bilateral collaborations, suggesting they contribute a defined technical role (likely process or synthesis work) within larger research networks. This profile indicates they are a reliable specialist who integrates into multi-partner projects without seeking administrative leadership.

Galchimia has built connections with 20 distinct partners across 10 countries through only two projects, indicating broad European exposure relative to their project volume. No single-country or repeat-partner concentration is visible in the data, suggesting they engage with diverse consortia rather than a fixed network.

What sets them apart

Galchimia occupies a rare niche as a chemistry SME with proven capability in both classical process scale-up and synthetic biology manufacturing — covering both the chemistry and biology sides of bio-based production. Based in Galicia, Spain, they bring industrial-scale process thinking to academic-heavy research consortia, bridging the gap between laboratory discovery and manufacturable output. For consortium builders, they represent a practical execution partner able to translate novel biosynthetic routes into scalable processes, which is a bottleneck in many bioeconomy and green chemistry projects.

Highlights from their portfolio

• SHIKIFACTORY100
  An ambitious synthetic biology project targeting 100 distinct compounds from a single metabolic pathway, requiring both deep metabolic engineering knowledge and the ability to rapidly prototype and validate diverse cell factory designs.
• NANOFACTURING
  Their largest single grant (€675,554) and earliest H2020 project, focused on the practically critical but often neglected challenge of scaling sustainable manufacturing processes to clinical-grade standards.